SCHEMBL830759

SCHEMBL830759

Nc1cc(/C=C/C(=O)CS(=O)(=O)c2cc3ccc(Cl)cc3[nH]c2=O)ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.39
GPR183 P32249 1/20 0.33
ALOX15 P16050 4/20 0.32
ESR1 P03372 2/20 0.32
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
PKM P14618 1/20 0.31
HPGD P15428 1/20 0.31
NPY1R P25929 1/20 0.31
NTSR1 P30989 1/20 0.31
NPY2R P49146 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC8 Q9BY41 1/20 0.31
BACE1 P56817 2/20 0.31
PYGL P06737 1/20 0.31
TUBB4A P04350 1/20 0.31
TUBB P07437 1/20 0.31
TUBA3C P0DPH7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL829872 1.00 DAO (0.39) DAOGPR183ALOX15ESR1MEN1
SCHEMBL829873 1.00 DAO (0.39) DAOGPR183ALOX15ESR1MEN1
SCHEMBL831369 0.89 DAO (0.44) DAOALOX15ESR1HDAC1HDAC8
SCHEMBL830547 0.89 DAO (0.44) DAOALOX15ESR1HDAC1HDAC8
SCHEMBL830548 0.89 DAO (0.44) DAOALOX15ESR1HDAC1HDAC8
SCHEMBL829842 0.85 MAPT (0.42) DAOMEN1ALDH1A1HPGDKMT2A
SCHEMBL829843 0.85 MAPT (0.42) DAOMEN1ALDH1A1HPGDKMT2A
SCHEMBL830963 0.85 MAPT (0.42) DAOMEN1ALDH1A1HPGDKMT2A
SCHEMBL830355 0.83 MAPT (0.43) DAOMEN1ALDH1A1KMT2ASMN1; SMN2
SCHEMBL830356 0.83 MAPT (0.43) DAOMEN1ALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US claimed
EP-1765804-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF Temple University of the Commonwealth System of Higher Education (US) 2007-03-28 EP claimed
WO-2005123077-A2 HETEROARYL SULFONES AND SULFONAMIDES AND THERAPEUTIC USES THEREOF TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2005-12-29 WO claimed
US-8143428-B2 Heteroaryl sulfones and sulfonamides and therapeutic uses thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2012-03-27 US disclosed
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232649-A1 Heteroaryl Sulfones and Sulfonamides and Therapeutic Uses Thereof SULT1E1, STS, CCNE1 DAO 3359/4885GPR183 3963/4885ALOX15 3728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.